A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

NCT05896527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

229

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: DC-806
OTHER: Placebo

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company